Daniel Razansky is a Full Professor at the Department of Information Technology and Electrical Engineering, ETH Zurich, leading the Professorship for Biomedical Imaging. His research spans engineering, physics, biology, and medicine, focusing on developing advanced in vivo imaging tools like optoacoustic tomography and ultrasound neuromodulation. His recent work emphasizes multi-scale functional and molecular imaging , with applications in neuroscience , Alzheimer’s disease , and stroke diagnostics . Collaborations include National Tsing Hua University and the EU Horizon consortium SWEEPICS. Current projects target hybrid imaging systems (e.g., MRI-MSOT) and image-guided neuromodulation. Scientific awards include the IPPA James Smith Prize for his contributions. His lab has secured significant grants, including a $2.5M NIH award and SNSF funding. He mentors PhD students like Quanyu Zhou and Eva Remlova, who have received accolades for their research. The Razansky Lab at ETH Zurich’s Preclinical Imaging Center explores medical microrobotics , dynamic fluid flow imaging , and neuroimaging techniques , aiming to bridge engineering with clinical applications.
Foteini Mourkioti is an Associate Professor at the University of Pennsylvania's Perelman School of Medicine , with a joint appointment in the Graduate Groups of Cell and Molecular Biology and Bioengineering . She co-directs the Musculoskeletal Regeneration Program at the Penn Institute of Regenerative Medicine and leads the McKay Orthopaedic Research Laboratory . Research Interests : Muscle Stem Cell Biology Mechanobiology Muscle Regeneration Telomere Biology in Muscular Diseases Fibrodysplasia Ossificans Progressiva (FOP) Cardiomyopathy and Aging Key Research Contributions : Developed the Pax7EGFP mouse model for real-time muscle stem cell tracking Discovered telomere shortening as a critical factor in Duchenne Muscular Dystrophy Elucidated the role of NF-κB in muscle stem cell dysfunction Identified Piezo1's role in stem cell morphological states Characterized fibro-adipogenic progenitor dynamics in FOP Scientific Awards : NIH/NHLBI R01 grant recipient (2019) NASA grant awardee (2020, 2017) American Heart Association grant (2017) Muscular Dystrophy Association grant (2019) University Research Foundation grant (2018) Publications & Collaborations : Over 25 publications in high-impact journals like Science Advances , Nature Protocols , and Cell Reports . Collaborates with Penn Cardiovascular Institute and Pennsylvania Muscle Institute.
Bruce Clurman, MD, PhD, serves as Executive Vice President, Chief Scientific Officer, and Deputy Director of Fred Hutchinson Cancer Center. He holds the Rosput Reynolds Endowed Chair and is a Professor in both the Translational Science and Therapeutics Division and Human Biology Division at Fred Hutch, with additional appointments as Professor in the University of Washington Department of Medicine and Adjunct Professor in Pathology. His educational background includes: BA in Philosophy, University of Virginia (1981) PhD in Viral Oncology, Cornell University Graduate School of Medical Sciences (1988) MD, Cornell University Medical College (1989) Residency at Brigham and Women’s Hospital, Boston Fellowship in Medical Oncology/Molecular Medicine at Fred Hutch and UW Dr. Clurman's research centers on cell cycle regulation and protein degradation mechanisms in cancer development. His lab investigates how ubiquitin-proteasome system dysregulation—particularly involving Fbw7 tumor suppressor, cyclin E, CDK2, and Wee1 kinases—drives oncogenesis. Current work focuses on exploiting DNA replication stress and mutations in cell cycle regulators to develop targeted therapies that selectively kill cancer cells while sparing healthy tissue. His major scientific recognitions include: W. M. Keck Foundation Distinguished Young Scholar (1999) National Cancer Institute Clinical Investigator Award José Carreras Fellowship James S. McDonnell Foundation Scholarship Election to American Society for Clinical Investigation (2005) As leader of the Clurman Lab, he directs multidisciplinary research integrating biochemistry, proteomics, and genetically engineered mouse models. He actively contributes to Fred Hutch's Immunotherapy, Pathogen-Associated Malignancies, and Translational Data Science Integrated Research Centers while maintaining clinical practice in blood cancer transplantation.
Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.
Pablo Perez-Pinera is an Associate Professor in Biomedical and Translational Sciences at the Carle Illinois College of Medicine, University of Illinois. He leads the Genome Engineering and Transcriptional Regulation Laboratory, focusing on developing gene editing technologies for treating neurodegenerative and neuromuscular diseases. His research integrates cutting-edge genome engineering tools with innovative delivery systems to address previously incurable conditions. Dr. Perez-Pinera's research interests center on developing CRISPR-based genome editing technologies for therapeutic applications. His laboratory specializes in base editing approaches for exon skipping, particularly targeting diseases like Duchenne muscular dystrophy, Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS. His team develops novel delivery systems using AAV vectors to enable precise in vivo genome editing, with a particular focus on neurological and muscular disorders. The lab's work bridges fundamental molecular biology with translational applications, aiming to move promising technologies from bench to bedside. His laboratory has made significant contributions to the field of therapeutic genome editing, particularly in developing the SPLICER platform for efficient exon skipping through simultaneous splice site editing. His publications demonstrate expertise in base editing for neurodegenerative diseases, with multiple first-author and corresponding author papers in high-impact journals. His research has been supported by several NIH grants including R01 GM131272, UL1 TR001422, R01 GM141296, among others. Dr. Perez-Pinera actively mentors a diverse team of researchers including postdoctoral fellows, graduate students, and undergraduates. His laboratory includes researchers such as Devyani Swami (Postdoctoral Fellow), Michael Gapinske, Jackson Winter, Shraddha Shirguppe, Angelo Miskalis, and others who contribute to various aspects of genome engineering research. His grant funding supports both basic research on genome editing mechanisms and translational work toward therapeutic applications. The Genome Engineering and Transcriptional Regulation Laboratory maintains state-of-the-art facilities for molecular biology, cell culture, and in vivo studies. The team collaborates extensively with clinicians and researchers across the University of Illinois campus to translate genome editing discoveries into potential therapies for patients suffering from neurodegenerative and neuromuscular conditions.
Hsei Di Law is a Research Fellow at the National Centre for Epidemiology and Population Health (NCEPH), part of the Australian National University (ANU). She is concurrently pursuing an MSc in Computational Data Analytics at the Georgia Institute of Technology . Her work focuses on data linkage, machine learning, and epidemiological study design using whole-of-population linked datasets. Research Affiliations National Centre for Epidemiology and Population Health (ANU) Centre of Epidemiology for Policy and Practice Linked Data for Better Health group Health Experience and Health Services Research collaborator Research Interests : Hsei Di Law's work centers on large-scale linked administrative datasets and longitudinal data analysis , with applications in environmental contamination (PFAS, asbestos), healthcare economics (out-of-pocket costs), and epidemiology of diseases. She specializes in integrating machine learning techniques with epidemiological study design to address policy-relevant questions. Publication Trends : Her recent publications (2025–2023) analyze healthcare affordability in Australia, PFAS environmental health impacts , and data linkage methodologies . Over 2022–2015, she studied cardiovascular risk under-treatment , COVID-19 healthcare outcomes , and immune system disorders using mouse models. Projects Led : She is involved in multiple projects, including the ACT Asbestos Health Study II , PFAS Health Study , and Whole-of-population linked data project . These projects examine the health effects of asbestos and PFAS contamination , healthcare utilization, and epidemiological modeling . Contact : Email: hsei-di.law@anu.edu.au Phone: +61 2 6125 0547 Location: Building 62A, Room 2.56, ANU
Kristina Schoonjans is an Associate Professor at EPFL’s School of Life Sciences, where she leads the Laboratory of Metabolic Signaling (UPSCHOONJANS). Her research focuses on the molecular mechanisms of bile acid signaling, nutrient sensing, and intermediary metabolism, particularly in the context of metabolic disorders such as obesity, fatty liver disease, and cancer. She investigates how the liver-gut-brain axis integrates metabolic signals through nuclear receptors and mitochondrial dynamics. Her research interests include: Bile acid signaling and its role as a hormonal regulator Nutrient and metabolite sensing in energy homeostasis Intermediary metabolism and metabolic disorders Role of nuclear receptors (e.g., TGR5, LRH-1) in liver, gut, and adipose tissue Mitochondrial dynamics and fission in metabolic regulation Organoid models for studying liver and intestinal metabolism Systems genetics using BXD mouse populations The most recent articles highlight a strong focus on bile acid signaling, particularly through TGR5 and LRH-1, in regulating metabolic health. Themes include the conversion of white fat to beige fat (beiging), hepatic tumorigenesis, mitochondrial fission, and the use of organoid and genetically engineered mouse models. There is a consistent emphasis on translational applications for obesity, fatty liver disease, and cancer. Scientific honors include: Windaus Prize from the Dr. Falk Foundation (2010, shared with Johan Auwerx) for the discovery of the signaling/endocrine function of bile acids Prof. Schoonjans actively supervises PhD students and has advised numerous doctoral candidates who have since completed their theses. Her lab is supported by multiple grants from Swiss and international funding agencies, including the Swiss National Science Foundation, EPFL, CONACYT, and the Foundation for Health and Education. She teaches in several doctoral programs at EPFL, including Life Sciences Engineering, and contributes to education through the SSV and EDBB/EDCB/EDMS-ENS programs. The Schoonjans Lab brings together scientists, doctoral assistants, and technicians working on projects related to metabolic signaling. The team uses advanced techniques such as genetically modified mouse models, organoid cultures, and multi-omics (metabolomics, proteomics, transcriptomics) to study the liver-gut and brain-liver axes. The lab has a strong track record of high-impact publications and collaborations with institutions worldwide.
Monica N. Fornier is a physician scientist at Memorial Sloan Kettering Cancer Center (MSK) specializing in breast medical oncology . With a clinical focus on improving outcomes for breast cancer patients, she has particular expertise in bone health related to cancer therapies. Fluent in English, Italian, and French, Dr. Fornier treats international patients and contributes to multidisciplinary care teams. Education: MD from University of Milan (Italy), residency and fellowship at University Hospital of Milan and MSK Certifications: Board-certified in Internal Medicine and Medical Oncology (Europe) Her research spans neoadjuvant endocrine therapy , bone loss prevention in cancer patients, and HER2-positive breast cancer treatment beyond trastuzumab. Recent publications address ER+/HER2- breast cancer immune responses, alopecia management in survivors, and regulatory T cell mechanisms . Dr. Fornier has received multiple Castle Connolly Top Doctor awards (2023-2025) and participates in MSK clinical trials for novel cancer treatments.
Uwe Himmelreich is a Full Professor at the Faculty of Medicine, KU Leuven , leading the Biomedical MRI unit. He is actively involved in the Medical Imaging Division , KU Leuven Brain Institute , KU Leuven Institute for Integration of Micro- and Nano-scale Technologies , and KU Leuven Cancer Institute . Role: Full Professor and Head of Biomedical MRI Affiliations: Faculty of Medicine, Medical Imaging Division, LBI, LIMNI, LKI His research spans neuroscience , cardiovascular imaging , and nano/micro-scale technologies . Key projects include: MindMAP: Radiotherapy-induced neurotoxicity in juvenile brains Preclinical cancer models for oral tumors Quantitative T2 mapping of lung disease in murine models Neuroinflammation and cognitive decline in cryptococcosis Resistance training effects on cortical thickness in aging cohorts His work integrates MRI , multi-photon microscopy , and novel contrast agents for longitudinal in vivo studies. Methodologies include vascular density mapping , proton therapy verification , and preclinical radiotherapy evaluation . Notable contributions include: 2025: JAK/STAT inhibition in malaria-induced inflammation 2025: Manganese-enhanced MRI for cardiac injury 2025: Quantitative lung imaging at 9.4T 2024: IVIM as vascular density marker in rat brain 2024: Phase-change ultrasound agents for proton therapy
Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.
Xenophon Papademetris is a Professor of Biomedical Informatics & Data Science and Radiology & Biomedical Imaging at Yale School of Medicine. He serves as Associate Director of Biomedical Imaging Data Sciences at Yale Biomedical Imaging Institute and directs the Medical Software and Medical Artificial Intelligence Certificate Program. PhD in Electrical and Information Sciences from Yale University (2000) BA from Cambridge University (1994) Postdoctoral Fellowship at Yale University (2002) His research focuses on medical image analysis, machine learning, and biomedical software development. He has developed tools like BioImage Suite Web and contributed to standards committees at the Association for the Advancement of Medical Instrumentation (AAMI). His work spans modalities including MRI, CT, PET, and optical imaging. Recent publications emphasize neuroimaging analysis, explainable AI in healthcare, and multimodal data integration across species. He leads NIH-funded research under the BRAIN Initiative (R24 MH114805) and has authored a textbook on Medical Software published by Cambridge University Press. IEEE Senior Member Yale Brown-Coxe Postdoctoral Fellowship Harding Bliss Prize for Excellence in Engineering He directs the BioImage Suite Project, creating web-based image analysis tools using JavaScript and WebAssembly. His teaching includes both academic courses and a Coursera program on Medical Software with over 14,000 enrollments.
Chen Ran, PhD, is an Assistant Professor in the Department of Neuroscience at Scripps Research in San Diego. His laboratory focuses on understanding how the brain processes internal sensory signals from visceral organs, such as hunger, satiety, nausea, and visceral pain. Using advanced techniques like in vivo two-photon calcium imaging, optogenetics, and circuit tracing, his team maps the functional architecture of brainstem circuits responsible for interoceptive processing. Key contributions include the discovery of a 'visceral homunculus' in the brainstem and the development of novel calcium indicators for high-resolution neuronal activity tracking. Education : PhD in Biology, Stanford University (2017) Bachelor of Science in Biology, Peking University (2011) Research Interests : Dr. Ran’s work integrates experimental and analytical approaches to decode how visceral stimuli are transduced into conscious sensations. Current projects investigate the coding logic of mechanical, chemical, and thermal signals from internal organs, with implications for developing therapies for obesity, diabetes, visceral pain, and eating disorders. The lab employs cutting-edge tools to visualize and manipulate neural circuits in awake behaving mice, linking circuit-level activity to physiological states. Awards & Honors : NARSAD Young Investigator Award (2022) NIH K01 Career Development Award (2023) Simons Collaboration on the Global Brain Award (2022) Harvard Brain Science Initiative Award (2021) Grants & Funding : Supported by NIH, Simons Foundation, and private philanthropy, his research bridges basic science and translational medicine. Current grants focus on brainstem circuit mapping and developing therapeutic targets for interoceptive disorders. Labs & Affiliations : Dr. Ran leads an interdisciplinary team at Scripps Research’s Neuroscience Department, collaborating with engineers, geneticists, and clinicians to advance interoceptive neuroscience.
Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.
Prof. Dr. Dr. Elisabeth Binder is the Director of the Max Planck Institute of Psychiatry and leads the Max Planck Research Group "Genes and Environment" in Munich, Germany. Her research focuses on molecular mechanisms underlying psychiatric disorders, particularly how genetic and environmental factors interact in disease development. Education: Medicine (University of Vienna), Neuroscience (Emory University) Affiliations: Max Planck Institute of Psychiatry, International Max-Planck Research School Translational Psychiatry, Graduate School of Systemic Neuroscience Research Interests: Elisabeth Binder investigates gene-environment interactions in psychiatric disorders, emphasizing early trauma and stress response. Her work employs next-generation sequencing, epigenetic analysis, and induced pluripotent stem cells to identify biological markers for disease prevention and treatment. Scientific Awards: Theodore Reich Young Investigator Award (2010) Max Hamilton Memorial Prize (2012) Eva King-Killam Research Award (2016) Carus Medal (2017) Ron the Kloet Award for Stress Research (2019) Leadership Roles: She is a member of the German National Academy of Sciences (Leopoldina), a Fellow of the American College of Neuropsychopharmacology, and serves on multiple international advisory committees and executive boards in psychiatry and neuroscience.
Dr. Timur Alexander Yorgan is a prominent researcher at the Department of Osteology and Biomechanics at University Medical Center Hamburg-Eppendorf (UKE). Holding a Dr. rer. nat. degree, he has established himself as a leading figure in bone biology with over 60 publications spanning from 2013 to 2025. His research is deeply integrated with key institutional research areas including the Hamburg Center of Neuroscience and immunology research networks at UKE. Dr. Yorgan's research focuses on skeletal development, bone remodeling, and genetic bone disorders, with particular emphasis on Wnt signaling pathways and their role in bone homeostasis. His work spans multiple approaches from molecular genetics to translational studies, investigating osteoblast and osteocyte biology, genetic mechanisms underlying disorders like osteogenesis imperfecta, and the effects of various mutations on skeletal integrity. Recent research has expanded into the gut-bone axis, mechanobiology of bone cells, and neuro-immune interactions affecting bone metabolism. Analysis of Dr. Yorgan's publication record reveals a consistent trajectory of high-impact research in bone biology. His work increasingly explores interdisciplinary connections between bone metabolism and other physiological systems, with growing emphasis on translational approaches for therapeutic interventions. The research demonstrates sophisticated use of mouse models and molecular techniques to unravel complex bone disorders and identify potential treatment targets. Dr. Yorgan appears to be actively involved in collaborative research across multiple institutions, as evidenced by his extensive publication record with numerous co-authors from various departments and institutions. His work is frequently published in high-impact journals including Journal of Bone and Mineral Research, Nature Communications, and Bone Research. The Department of Osteology and Biomechanics at UKE, where Dr. Yorgan is based, is part of a vibrant research ecosystem that includes the Hamburg Center of Neuroscience and other key research networks focusing on immunology, oncology, and cardiovascular research. This collaborative environment enables interdisciplinary approaches to understanding skeletal disorders and developing novel therapeutic strategies.
